Deep­en­ing US foot­print, As­traZeneca-part­nered French biotech In­nate shoots for $100M IPO

Fresh off of a 20th birth­day cel­e­bra­tion, French biotech In­nate Phar­ma filed for a US IPO worth up to $100 mil­lion. They de­tailed in their fil­ings a strat­e­gy to roll cash in­to pre­clin­i­cal work, ad­vanc­ing the tri­als for two drugs tar­get­ing blood can­cer and sol­id tu­mors and fur­ther test­ing the check­point in­hibitor mon­al­izum­ab, while al­so build­ing a com­mer­cial in­fra­struc­ture to mar­ket and cap­i­tal­ize on their trade­mark leukemia drug Lu­mox­i­ti.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER